Jim Cramer recently discussed Abbott Laboratories (NYSE:ABT), praising it as one of the most reliable healthcare companies with excellent growth in device and pharmaceuticals. He highlighted Abbott’s $23 billion acquisition of cancer screening firm Exact Sciences, calling it “very, very important.”

Cramer emphasized the significance of Abbott’s deal with Exact Sciences, noting that it strengthens Abbott’s weakest vertical and provides a consistent revenue stream. He believes the acquisition, despite its high price tag, is beneficial for early detection and is supported by Medicare and insurance companies.

While ABT shows potential as an investment, some believe other AI stocks offer greater promise for higher returns with limited downside risk. For those seeking a cheap AI stock benefiting from Trump tariffs and onshoring, a free report on the best short-term AI stock is available.

For more insights on potential stocks that could double in the next three years or hidden AI stocks to buy now, check out Insider Monkey’s articles. Note: No disclosures in this article.

Read more at Yahoo Finance: Abbott’s (ABT) Exact Sciences Deal is “Very, Very Important,” Says Jim Cramer